The immunoSCAPE Story
immunoSCAPE was spun-out from the Agency of Science, Technology and Research (A*STAR) in Singapore. Dr Evan Newell, our co-founder, developed the core technology based on methods for specific T cell identification. We are committed to the continuous development of data analysis tools and immune profiling solutions to improve the robustness of our read-outs and the value we offer.
We launched in the spring of 2017 and have expanded our global reach with customers in the US, Europe, Africa, and Asia. immunoSCAPE Inc was launched in Cambridge, MA, US in 2018.
Who We Are
We are scientists – passionate in our pursuit of knowledge and discovery for the sake of the patients we ultimately serve.
- We demonstrate INTEGRITY in our conduct and our work.
- We continuously INNOVATE to solve problems and improve patient outcomes.
- We LISTEN to our partners and colleagues to improve the way we meet needs.
Executive Team
Choon Peng Ng
Co-founder and CEO
Choon has extensive experience in financial management and marketing in small and large international organizations, including as a start-up CEO.
Alessandra Nardin
Co-founder and COO
Alessandra is a tumor immunologist with international experience in various aspects of translational immunology and business development, in academic and industry settings.
Michael Fehlings
Co-founder and Director, Scientific Affairs
Michael is an immunologist with in-depth and hands-on expertise in mass cytometry and multiplexing tetramer technology in the fields of infectious diseases and cancer.
Mathew Cobbett
VP, North America
Matt is an experienced life science business development executive and an entrepreneur.
Board of Directors
Choon Peng Ng
Chairperson
Choon has extensive experience in financial management and marketing in small and large international organizations, including as a start-up CEO.
Evan Newell
Director
Evan pioneered the use of mass cytometry for high-dimensional immune profiling in Stanford and A*STAR; his research focus is T cell immunology and over the years has developed combinatorial tetramer coding solutions and many analytical tools. He is currently Principal Investigator at the Vaccine and Infectious Disease Division of Fred Hutch.
Alessandra Nardin
Director
Alessandra is a tumor immunologist with international experience in various aspects of translational immunology and business development, in academic and industry settings.
Naonori Kurokawa
Director
Nori is a partner at University of Tokyo Edge Capital (UTEC), where he manages investment focused on physical science and advanced technology.
Advisory Board
Evan Newell
Co-founder and Scientific Advisor
Evan pioneered the use of mass cytometry for high-dimensional immune profiling in Stanford and A*STAR; his research focus is T cell immunology and over the years has developed combinatorial tetramer coding solutions and many analytical tools. He is currently Principal Investigator at the Vaccine and Infectious Disease Division of Fred Hutch.
Jack T. Ball
Strategic Advisor
Mr Jack Ball was Chief Commercial Officer of Accuri Cytometers. Mr. Ball has a long and proven record for bringing life science products to market and capitalizing on existing product potential. He was CEO of Amnis Corporation, a venture backed technology start-up developing high-end imaging flow cytometers. He has also served as CCO for Molecular Probes, Inc., the world leader in reagents for cell analysis, including flow cytometry consumables. Prior to that he was with Orchid Biosciences as Sr. VP and General Manager with Amersham Pharmacia Biotech Inc., where he rose to President, Region North America and was responsible for sales, marketing, and customer support for all products sold in North America
Graeme R. Martin
Strategic Advisor
Dr. Graeme Martin is President of Takeda Ventures Inc., the venture investment arm of Takeda Pharmaceutical Company, Ltd. He has overseen investment in 26 early-stage companies of strategic importance to Takeda. During more than 35 years in multinational pharmaceutical and biotech companies in Europe and the United States, Dr. Martin has worked on three IND candidates, including Zomig®, now marketed worldwide for migraine management. He is the author of more than 85 peer-reviewed publications and book chapters, and received his bachelor of science degree in pharmacology from the University of Bath, UK and his doctorate from University College, London, UK.
Andreas Wallnoefer
Strategic Advisor
Andreas was previously Global Head of Clinical Research & Exploratory Development in Roche, more recently at the University of Basel and on the Board of several biotech companies.
Soo Khee Chee
Strategic Advisor
Prof Soo was founding Director of National Cancer Centre Singapore and key contributor in the establishment of Duke-NUS School of Medicine. He is a renowned cancer clinician and has been critical in placing Singapore to the forefront of translational medicine.
Juan Harrison
Strategic Advisor
Mr. Juan Harrison is a biotechnology and pharmaceutical executive focused on company
formation, strategy, partnering, venture investment and licensing transactions. He is currently
providing advisory services to several early stage companies, venture capital enterprises and
academic centers. He was previously Vice President and Head of Strategic Academic Alliances
at Takeda Pharmaceuticals where he was responsible for establishing several broad drug
discovery alliances, including the Tri-Institutional Therapeutics Discovery Institute (Weill Cornell
Medicine, Rockefeller University and Memorial Sloan Kettering Cancer Center), the Alliance for
Innovative Medicines (Stanford University), the Seattle Partnership for Research in Innovative
Therapeutics (SPRInT, including the Fred Hutchinson Cancer Research Center, the University of
Washington, and Seattle Children’s Hospital), and the Dana Farber Cancer Institute. Before
leading Takeda’s SAA, he was VP at Takeda Ventures where he invested in several companies
including Envoy Therapeutics, later acquired by Takeda. Mr. Harrison has been working in the
biopharmaceutical industry since 1985 and has held senior positions in Alza Pharmaceuticals,
Connetics, PowderJect and XenoPort. He received a BS in Combined Science from Santa Clara
University with emphasis in Chemistry and Biochemistry.
formation, strategy, partnering, venture investment and licensing transactions. He is currently
providing advisory services to several early stage companies, venture capital enterprises and
academic centers. He was previously Vice President and Head of Strategic Academic Alliances
at Takeda Pharmaceuticals where he was responsible for establishing several broad drug
discovery alliances, including the Tri-Institutional Therapeutics Discovery Institute (Weill Cornell
Medicine, Rockefeller University and Memorial Sloan Kettering Cancer Center), the Alliance for
Innovative Medicines (Stanford University), the Seattle Partnership for Research in Innovative
Therapeutics (SPRInT, including the Fred Hutchinson Cancer Research Center, the University of
Washington, and Seattle Children’s Hospital), and the Dana Farber Cancer Institute. Before
leading Takeda’s SAA, he was VP at Takeda Ventures where he invested in several companies
including Envoy Therapeutics, later acquired by Takeda. Mr. Harrison has been working in the
biopharmaceutical industry since 1985 and has held senior positions in Alza Pharmaceuticals,
Connetics, PowderJect and XenoPort. He received a BS in Combined Science from Santa Clara
University with emphasis in Chemistry and Biochemistry.
John Freshley
Strategic Advisor
Based in Ann Arbor, Michigan, John Freshley is a high-energy entrepreneur, company builder
and leader with 20+ years experience in a variety of healthcare-focused companies. He has
founded, launched, and/or led 8 early stage life science companies, including Compendia
Bioscience through its acquisition by Life Technologies (now Thermo Fisher).